Fusion Pharmaceuticals
Targeted alpha therapeutics (TAT) for the treatment of chemotherapy resistant cancers.
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 1 % | 42 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (5651 %) | (5999 %) | (4236 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (5628 %) | (5997 %) | (4589 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | 3914 % | 4031 % | 3390 % |
Source: Company filings or news article
Related Content
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing next-generation precision medicines for cancer treatment. The company operates in the biopharmaceutical market, focusing on creating innovative radiotherapeutics that target multiple tumor types. Fusion Pharmaceuticals serves cancer patients and healthcare providers, aiming to improve patient outcomes and quality of life. The business model revolves around research and development, leveraging proprietary linker technology to enhance the safety and efficacy of their treatments. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of their therapeutic products. The company is a spin-out from the Centre for Probe Development and Commercialization (CPDC), which provides it with a robust supply chain and extensive expertise in manufacturing. Fusion Pharmaceuticals is committed to pushing the boundaries of science to offer revolutionary cancer treatments.
Keywords: precision medicines, radiotherapeutics, cancer treatment, proprietary linker technology, clinical-stage, biopharmaceutical, tumor targeting, patient outcomes, healthcare providers, CPDC.